Axiom Investors LLC DE Sells 62,418 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Axiom Investors LLC DE trimmed its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 54.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 53,224 shares of the company's stock after selling 62,418 shares during the quarter. Axiom Investors LLC DE owned about 0.06% of Syndax Pharmaceuticals worth $704,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SNDX. R Squared Ltd bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter worth $26,000. Quantbot Technologies LP bought a new position in shares of Syndax Pharmaceuticals in the third quarter valued at $49,000. Cape Investment Advisory Inc. grew its holdings in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock valued at $85,000 after buying an additional 3,927 shares during the last quarter. KBC Group NV increased its position in shares of Syndax Pharmaceuticals by 104.8% during the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after acquiring an additional 3,559 shares in the last quarter. Finally, E Fund Management Co. Ltd. raised its holdings in shares of Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after acquiring an additional 1,583 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have issued reports on SNDX. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. StockNews.com upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a report on Wednesday. JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Scotiabank cut their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, Citigroup reduced their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $36.20.

Remove Ads

Syndax Pharmaceuticals Stock Performance

NASDAQ SNDX traded down $1.21 on Friday, hitting $11.25. 1,817,612 shares of the stock traded hands, compared to its average volume of 1,529,168. The business's fifty day moving average is $14.13 and its two-hundred day moving average is $15.67. Syndax Pharmaceuticals, Inc. has a 12 month low of $11.09 and a 12 month high of $25.07. The firm has a market capitalization of $967.77 million, a price-to-earnings ratio of -3.10 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.79). The business had revenue of $7.68 million for the quarter, compared to analyst estimates of $86.32 million. Analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insider Activity

In related news, CFO Keith A. Goldan sold 3,777 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares of the company's stock, valued at approximately $1,406,563. This represents a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Neil Gallagher sold 4,618 shares of the firm's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company's stock, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock worth $336,087 over the last ninety days. Company insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).